BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$290.86 USD
-1.89 (-0.65%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $291.08 +0.22 (0.08%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 4 |
Average Target Price | $426.25 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 97 of 252 |
Current Quarter EPS Est: | 2.04 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
Not Identified | Not Identified | Not Identified | Not Identified | Not Identified |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.